Mymetics Corporation Stock Other OTC
Equities
MYMX
US62856A1025
Biotechnology & Medical Research
Sales 2021 | 430K 460K | Sales 2022 | 1.03M 1.1M | Capitalization | 8.51M 9.11M |
---|---|---|---|---|---|
Net income 2021 | -4M -4.28M | Net income 2022 | -4M -4.28M | EV / Sales 2021 | 177 x |
Net Debt 2021 | 67.1M 71.77M | Net Debt 2022 | 71.68M 76.67M | EV / Sales 2022 | 78 x |
P/E ratio 2021 |
-1.86
x | P/E ratio 2022 |
-1.77
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 48.72% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 09-06-30 | |
Mario Amacker
PRN | Corporate Officer/Principal | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Staehelin
BRD | Director/Board Member | 76 | 07-07-01 |
Ulrich Burkhard
BRD | Director/Board Member | 63 | 12-03-22 |
Marcel B. Rüegg
BRD | Director/Board Member | - | 23-01-15 |
1st Jan change | Capi. | |
---|---|---|
-1.84% | 103B | |
+0.40% | 95.71B | |
+1.69% | 22.02B | |
-17.18% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.94% | 15.52B | |
+3.65% | 13.86B | |
+35.67% | 12.04B |